Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 8/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 3/20 | 0.39 |
| ▸ | AMPD2 | Q01433 | 2/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5983024 | 0.99 | TNF (0.42) | TNFCYP1A2ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL5983224 | 0.99 | TNF (0.42) | TNFCYP1A2ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL5982887 | 0.99 | TNF (0.42) | TNFCYP1A2ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL5982629 | 0.95 | CYP1A2 (0.42) | TNFCYP1A2TBXAS1NR1I2PGR | |
| SCHEMBL5982037 | 0.89 | KAT2B (0.41) | TNFCYP1A2ALDH1A1TSHRCYP4F2 | |
| SCHEMBL5981938 | 0.89 | DGKA (0.42) | TNFALDH1A1 | |
| SCHEMBL5982840 | 0.87 | DGKA (0.45) | TNFALDH1A1TSHR | |
| SCHEMBL5981563 | 0.87 | DGKA (0.45) | TNFALDH1A1TSHR | |
| SCHEMBL5982610 | 0.87 | DGKA (0.45) | TNFALDH1A1TSHR | |
| SCHEMBL5982935 | 0.85 | KAT2B (0.43) | ALDH1A1TSHRFAAHAMPD2TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1600451-A2 | Synthesis of 2'-deoxy-l-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1600452-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | PHARMASSET, INC. | 2005-04-28 | — | — | US | disclosed |
| EP-1232166-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | Pharmasset Limited (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001034618-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | PHARMASSET LIMITED (US) | 2001-05-17 | — | — | WO | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| EP-0552765-B1 | Benzimidazoles, pharmaceutical compositions containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1996-08-14 | — | — | EP | disclosed |
| US-5459147-A | Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma | DR. KARL THOMAE GMBH (DE) | 1995-10-17 | — | — | US | disclosed |
| EP-0560330-A2 | Substituted benzimidazolyl derivatives, therapeutic agents containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-09-15 | — | — | EP | disclosed |
| EP-0556789-A2 | Substituted biphenyl derivatives, therapeutic agents containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-08-25 | — | — | EP | disclosed |
| EP-0552765-A1 | Benzimidazoles, pharmaceutical compositions containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | CCNH, ADAR, NSUN2 | TNF 4224/4885CYP1A2 2603/4885ALDH1A1 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.